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Abstract
Background: The aim of this study was to identify predictors of prolonged disease control after discontinuation of
tumor necrosis factor inhibitor (TNFi) treatment in patients with rheumatoid arthritis (RA).
Methods: Post-hoc analysis of 439 RA patients (67.3% rheumatoid factor positive) with longstanding RA in remission
or with stable low disease activity, randomized to stopping TNFi treatment in the multicenter POET trial. Prolonged
acceptable disease control was defined as not restarting TNFi treatment within 12months after stopping. Baseline
demographic and disease-related variables were included in univariate and multivariate logistic regression analysis for
identifying predictors of relapse.
Results: One year after baseline, 220 patients (50.1%) had not restarted TNFi treatment. Use of an anti-TNF monoclonal
antibody (versus a receptor antagonist, OR = 2.41; 95% CI: 1.58–3.67), ≤10 yrs. disease duration (OR = 2.15; 95% CI: 1.42–
3.26) and low or moderate multi-biomarker disease activity (MBDA) scores (OR = 2.00; 95% CI: 1.10–3.64) at baseline were
independently predictive of successful TNFi discontinuation (area under the receiver operating characteristic curve = 0.66;
95% CI: 0.61–0.71). Results were similar when using no physician-reported flare as the criterion. TNFi-free survival was
significantly different for patient groups based on the number of predictors present, ranging from 21.4% of patients with
no predictor present to 66.7% of patients with all three predictors present.
Conclusion: Patients using an anti-TNF monoclonal antibody, with shorter disease duration and low or moderate
baseline MBDA score are most likely to achieve prolonged disease control after TNFi discontinuation.
Trial registration: Netherlands Trial Register NTR3112, 21 October 2011.
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Background
Treatment options and outcomes in rheumatoid arthritis
(RA) have improved markedly over the last decades [1–3].
Particularly the use of conventional synthetic disease modi-
fying anti-rheumatic drug (csDMARDs) in combination
with the more expensive biological agents (bDMARDs
such as tumor necrosis factor inhibitors (TNFi) has been
shown to be effective in reducing disease activity, improv-
ing physical function, and slowing radiographic damage
[4–6]. In practice, patients achieving low disease activity
(LDA) or even remission usually continue this combination
therapy permanently. This, however, may lead to unneces-
sary treatment and resource use, as several studies have
suggested that a substantial number of RA patients in sus-
tained remission or LDA can taper or altogether stop their
TNFi without experiencing a disease flare [7, 8].
Although current guidelines suggest that tapering or
withdrawal of bDMARDs can be considered for patients in
persistent remission [9], where persistent remission is not
explicitly defined, validated predictors of successful discon-
tinuation are needed to successfully implement practical
stopping rules in daily clinical practice [10]. A number of
studies have already examined predictors of successful
TNFi discontinuation, but it remains a challenge to judge
which patients can effectively and safely stop their TNFi
without incurring a flare of the disease [11]. A recent sys-
tematic review found no consistently strong predictors for
successful dose reduction or discontinuation [12]. Only
shorter disease duration [13–15], less or no erosive disease
[14–16], and lower disease activity [14–17] at baseline have
been shown in more than one study to predict successful
TNFi discontinuation. Additionally, single studies have
found that younger age [14], normal body mass index
(BMI) [16], non-smoking [15], anti-cyclic citrullinated pep-
tide antibodies (ACPA) negativity [17, 18], shorter [15] or
longer [19] TNFi treatment, and initial (versus delayed)
TNFi treatment [13] were associated with successful TNFi
discontinuation. Finally, two studies have found a tendency
for more relapses among female patients [13, 17].
Moreover, two main types of TNFi with different mecha-
nisms of action are used in RA: anti-TNF monoclonal anti-
bodies versus soluble TNF receptors (receptor antagonist).
Monoclonal antibody agents like adalimumab and inflixi-
mab bind specifically to TNF, while the receptor fusion
protein etanercept, functioning as a decoy receptor, binds
to circulating TNF and prevents it from interacting with a
cell surface receptor [20–23]. Adalimumab and etanercept
are currently the most frequently prescribed TNFi and gen-
erally demonstrate comparable effectiveness [24, 25]. Previ-
ous discontinuation studies, however, generally examined
one specific TNFi agent only or did not examine possible
differences in the predictive value of the type of TNFi (anti-
TNF monoclonal antibody or receptor antagonist) for
successful discontinuation.
Recently, the POET trial showed that, although stop-
ping TNFi treatment in patients with established RA in
remission or with stable low disease activity resulted in
substantially more flares than did continuation of TNFi,
around half of the patients could successfully stop for at
least 12 months [26]. The aim of the current post-hoc
study was to identify baseline predictors of prolonged
disease control after discontinuation of TNFi.
Methods
Patients and study design
We used data from the Dutch pragmatic POET trial, regis-
tered in the Netherlands Trial Register (NTR3112) [26].
This multicenter trial randomized RA patients with stable
LDA, as measured with the 28-joint Disease Activity Score
using the erythrocyte sedimentation rate (DAS28-ESR)
[27], in a ratio of 2:1 to either discontinuing or continuing
TNFi treatment. For those patients randomized to stopping
TNFi, concomitant treatment with csDMARDs was contin-
ued. Eligible patients had to fulfill the ACR 1987 criteria
for RA, be 18 years or older, and have received TNFi treat-
ment for ≥1 year. Patients also needed to have stable LDA
for ≥6months before inclusion, which was operationalized
as either two DAS28-ESR scores < 3.2 or the rheumatolo-
gist’s clinical judgment of remission or stable low disease
activity with at least one C-reactive protein (CRP) measure-
ment < 10mg/L in the last 6months. Finally, no dosage
changes were allowed to have occurred for csDMARDs or
corticosteroids in the 6months prior to inclusion.
A total of 531 patients were randomized to the stop
group [26]. In case of a disease flare, defined as a DAS28-
ESR score ≥ 3.2 with an increase > 0.6 [28], the treating
rheumatologist could re-initiate TNFi treatment. As the
current study aimed to identify patient and clinical charac-
teristics predictive of prolonged disease control after dis-
continuation of TNFi treatment, only the data from 439
patients randomized to the stop group and for whom
baseline serum samples were collected to measure the
multi-biomarker disease activity (MBDA) score [29] were
used. Baseline characteristics were comparable between
the included 439 patients with and the 92 patients without
an available baseline MBDA measurement [30].
Measures
Included patients were examined by the rheumatologist
and rheumatology nurse at baseline and return visits were
scheduled at 3, 6, 9 and 12months or earlier if the symp-
toms suggested a disease flare. The following measure-
ments were collected at baseline: age, sex, weight, height,
body mass index (BMI), disease duration, rheumatoid fac-
tor (RF) and ACPA status, erosive disease (yes/no) and
medication use, including the type of TNFi (antibody vs.
receptor antagonist) and concomitant csDMARD use. In a
substantial subsample, the MBDA score was assessed at
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baseline. The MBDA score is a novel test that measures
12 biomarkers in serum to assess disease activity in
patients with rheumatoid arthritis [29]. The scoring algo-
rithm generates a total score from 1 to 100, with defini-
tions for low (< 30), moderate (30 to 44) and high (> 44)
disease activity [31].
Standard disease activity measurements were collected at
every visit and consisted of a 28-joint tender and swollen
joint count (TJC28 and SJC28), laboratory measurement of
the ESR (mm/h) and CRP (mg/l) and a patient-reported
general health assessment on a 100-mm visual analog scale
(VAS-GH). The TJC28, SJC28, ESR and VAS-GH were
used to calculate the DAS28-ESR as a composite index of
disease activity [27]. Physician-reported flares and medica-
tion changes were continuously recorded.
Statistical analysis
Successful discontinuation was defined as not restarting
TNFi treatment within 12months after stopping. First,
univariate logistic regression analyses were performed to
examine associations between potential baseline predic-
tors and successful 12-month TNFi discontinuation. The
following patient and clinical variables were considered:
type of TNFi (anti-TNF monoclonal antibody (adalimu-
mab, infliximab, golimumab or certolizumab)) vs. recep-
tor antagonist (etanercept), concomitant csDMARD use,
female sex, younger age (≤60 yrs.), shorter disease dur-
ation (≤10 yrs.), RF negativity, ACPA negativity, non-
erosive disease, normal weight (BMI = 18.5–25), first
TNFi agent, deep remission (DAS28 ≤ 1.98) [32, 33], and
low or moderate MBDA score (≤44) [30]. To facilitate
the interpretation of odds ratios (ORs), continuous pre-
dictors were dichotomized by median split (DAS28-ESR,
age, disease duration) or previously established relevant
cut-off points (BMI, MBDA). ORs are classified as weak
when about 1.5, moderate when about 2.5, strong when
about 4 and very strong when about 10 [34]. Additional
separate models were run to test for possible interac-
tions between each predictor and type of TNFi. Predic-
tors univariately associated with outcome (P < 0.10)
were included in a multivariate logistic regression model
to identify independent predictors. The multivariate
model was reduced by excluding predictors from the
model with P > 0.10 (backward deletion), and the good-
ness of fit of the final model was estimated using the
Hosmer and Lemeshow test [35], where a non-
significant result indicates support for the model. The
predictive ability of the model was examined using the
area under the receiver operating characteristic (ROC)
curve. All regression analyses were based on observed
data. As 38 patients (8.7%) had missing baseline values
on laboratory and radiographic erosion data, the multi-
variate model was repeated using multiple imputation
with 10 imputed datasets. Since results were very similar
to non-imputed data, only the results from observed
data are presented. As a sensitivity analysis, the final
multivariate model was repeated using no physician-
reported flare within 12 months after stopping as the
dependent variable. To further explore the prognostic
value of the remaining predictors, TNFi-free survival
based on the number of predictors present was exam-
ined using Kaplan-Meier survival analysis. Between-
group difference in survival was tested using the log
rank test. Since MBDA testing is not common in many
rheumatology practices, the multivariate and survival
analyses were repeated without MBDA as a predictor.
All statistical calculations were performed using SPSS
23.
Results
Table 1 summarizes the baseline characteristics of the
patients (n = 439). Median age and disease duration was
60 and 10 years, respectively. Approximately 60% of the
patients used an antibody agent, most frequently adali-
mumab, while 40% used etanercept. Most patients were
on their first TNFi. In total, 219 (49.9%) of the patients
restarted their TNFi within 12 months, while at least one
physician-reported flare was reported for 251 (57.2%)
patients. Forty-four patients with a physician-reported
flare (17.5%) did not restart their TNFi, while no
physician-reported flare was recorded for 12 patients
who restarted TNFi (6.4%).
Antibody type TNFi, shorter disease duration, non-
erosiveness and low or moderate MBDA were weakly to
moderately associated with successful discontinuation, de-
fined as not restarting TNFi treatment within 12months
after stopping in univariate regression analysis (Table 2).
No interactions with type of TNFi were significant and sep-
arate univariate analyses for both types of TNFi showed
that the predictive value of individual variables was similar
for patients discontinuing an antibody agent or etanercept.
However, MBDA ≤44 was significantly predictive only in
patients discontinuing etanercept (OR = 3.69; 95% CI:
1.34–10.18; P = 0.012) and not in patients discontinuing an
antibody agent (OR = 1.68; 95% CI: 0.81–3.45; P = 0.162).
In multivariate analysis, non-erosiveness lost its sig-
nificance (OR = 1.34; 95% CI: 0.85–2.11; P = 0.212). Type
of TNFi, shorter disease duration and low or moderate
MBDA scores remained independently predictive of suc-
cessful discontinuation, with type of TNFi being the
strongest predictor (Table 3). The area under the ROC
curve showed a modest predictive ability of 0.66 for
these three variables. This decreased to 0.65 when omit-
ting MBDA, suggesting rather limited added value of
MBDA as a predictor for biologic-free disease control
above and beyond type of TNFi and disease duration.
Logistic regressions with disease duration and MBDA as
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continuous predictors demonstrated very similar results,
with erosiveness again losing significance and type of
TNFi, shorter disease duration and lower MBDA scores
remaining independently predictive of successful discon-
tinuation [see Additional file 1].
As a sensitivity analysis, using ‘no physician-reported
flare’ as the criterion for successful TNFi discontinuation
resulted in similar findings in the total sample, with the
same three predictors remaining significant in multivari-
ate analysis. However, the predictive value of the vari-
ables tended to be slightly lower with ORs of 1.86 (95%
CI: 1.24–2.79; P = 0.003), 1.78 (95% CI: 1.18–2.70; P =
0.006) and 2.49 (95% CI: 1.35–4.59; P = 0.003) for anti-
body TNFi, shorter disease duration and low or moder-
ate MBDA score, respectively.
TNFi-free survival was significantly different (log
rank = 43.9, P < 0.001) for patient groups based on the
number of predictors present (Fig. 1). TNFi-free survival
rates were 21.4% in patients with no predictor present
(n = 14), 31.7% in patients with one predictor (n = 104),
52.6% in patients with two predictors (n = 213), and
66.7% in patients with three predictors (n = 108) present.
Fairly similar results and differences between groups (log
rank = 33.9, P < 0.001) were obtained in TNFi-free sur-
vival when using only antibody type TNFi and shorter
disease duration as predictors. In this analysis, TNFi-free
survival rates were 32.1% in patients with no predictor
present (n = 84), 48.5% in patients with one predictor
(n = 231), and 65.3% in patients with both predictors
(n = 124) present.
Discussion
The POET study previously demonstrated that in patients
with established RA in sustained remission or with stable
low disease activity, as defined by the DAS28-ESR,
approximately 50% of the patients could successfully stop
their TNFi for at least 12months [26]. However, with the
consequential fifty-fifty chance of relapsing, it would be
helpful to identify patient and clinical predictors of pro-
longed disease control after discontinuation of TNFi. This
post-hoc analysis showed that the type of TNFi (anti-TNF
monoclonal antibody vs. receptor antagonist) being used,
RA disease duration and the MBDA score at the time of
Table 1 Baseline characteristics of the patients (N = 439)
Female, n (%) 296 (67.4%)
Age (yrs.), mean (SD) 59.8 (10.8)
Disease duration (yrs.), median (IQR) 10 (6–17)
BMI, mean (SD) 25.9 (4.3)
Normal BMI (18.5–25), n (%) 174 (39.6%)
RF positive, n (%) 270 (67.3%)
ACPA positive, n (%) 277 (69.1%)
Erosive disease, n (%) 252 (62.8%)
ESR, median (IQR) 9.0 (5–17)
TJC28, median (IQR) 0 (0–1)
SJC28, median (IQR) 0 (0–0)
PGA, median (IQR) 20.7 (9.0–28.1)
DAS28-ESR, mean (SD) 2.0 (0.8)
MBDA score, mean (SD) 30.2 (12.6)
Low (< 30) or moderate (30–44), n (%) 375 (85.4%)
Type of TNFi, n (%)
Etanercept 176 (40.1%)
Adalimumab 225 (51.3%)
Infliximab 22 (5.0%)
Golimumab 14 (3.2%)
Certolizumab 2 (0.5%)
Number of TNFi, n (%)
1st 379 (86.5%)
2nd 50 (11.4%)
3rd 9 (2.1%)
csDMARD, n (%)
Methotrexate 362 (82.5%)
Methotrexate + glucocorticoids 20 (4.6%)
Glucocorticoids 6 (1.4%)
Other csDMARD 29 (6.6%)
No DMARD 22 (5.0%)
TNFi tumor necrosis factor-alpha inhibitors, DAS28 disease activity score in 28
joints, BMI body mass index, RF rheumatoid factor, ACPA anti-cyclic
citrullinated peptide antibodies, ESR erythrocyte sedimentation rate, CRP C-
reactive protein, TJC28 28-joint tender joint count, SJC28 28-joint swollen joint
count, PGA patient global assessment, MBDA multi-biomarker disease activity,
csDMARD conventional synthetic disease modifying anti-rheumatic drug
Table 2 Univariate associations of baseline variables with
successful TNFi discontinuation
Predictor OR 95% CI P
anti-TNF monoclonal antibodya 2.26 1.53–3.34 < 0.0001
Concomitant DMARD 1.21 0.51–2.85 0.670
Female sex 1.07 0.72–1.60 0.735
Younger age (≤60 yrs.) 1.17 0.80–1.70 0.417
Shorter disease duration (≤10 yrs.) 2.00 1.34–2.98 0.001
RF negative 1.14 0.75–1.74 0.530
ACPA negative 1.06 0.70–1.62 0.775
Non-erosive 1.62 1.08–2.44 0.020
Normal weight (BMI 18.5–25) 1.35 0.92–1.98 0.128
First TNFi 1.23 0.71–2.13 0.461
DAS28 deep remission (DAS28≤ 1.98) 1.21 0.83–1.77 0.314
Low or moderate MBDA (≤44) 2.32 1.32–4.05 0.003
aReference category is receptor antagonist
TNFi tumor necrosis factor-alpha inhibitors, csDMARD conventional synthetic
disease modifying anti-rheumatic drug, RF rheumatoid factor, ACPA anti-cyclic
citrullinated peptide, BMI body mass index, DAS28 disease activity score in 28
joints, MBDA multi-biomarker disease activity
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discontinuation of TNFi were significantly associated with
success of stopping. Approximately 70% of patients who
were on an anti-TNF monoclonal antibody, with a disease
duration of < 10 years and a MBDA score ≤ 44 were able to
successfully stop their TNFi, while conversely 80% of pa-
tients on a TNFi receptor antagonist, with a disease dur-
ation of ≥10 years and a MBDA score > 44 restarted their
TNFi within 12months of stopping.
Several other studies have previously explored potential
predictors of disease relapse after TNFi discontinuation
[11, 12]. Multiple studies found shorter disease duration,
RF positivity, non-smoking, erosive disease and normal
body mass index (BMI) to be predictive of successful TNFi
discontinuation [14, 16]. In the current study, shorter dis-
ease duration was also a predictor of successful discontinu-
ation, but RF positivity and normal BMI were not. Erosive
disease was univariately associated with restarting TNFi,
but did not remain a unique predictor in the final multi-
variate model.
Higher clinical disease activity at the time of discontinu-
ation has also previously been identified as a predictor, al-
though results varied considerably between studies [13, 14,
36]. In the current study, higher baseline DAS28-ESR
scores were not associated with the criterion of restarting
TNFi treatment within 12months. However, a high MBDA
score at the time of TNFi discontinuation was predictive of
restarting TNFi. Several previous studies found that MBDA
scores may be elevated when conventional clinical mea-
sures indicate remission or LDA [18, 37–39]. Furthermore,
these patients were found to be at increased risk for pro-
gressive joint damage [37–39]. In patients with high base-
line MBDA scores at the time of TNFi discontinuation in
POET, discontinuation may have allowed a resurgence of
subclinical residual inflammation and the subsequent need
to restart TNFi treatment [18].
At the time of the analysis, the type of TNFi, i.e. anti-
TNF monoclonal antibody vs. receptor antagonist, had not
been previously identified as a predictor of successful TNFi
discontinuation. Very recently, however, Hashimoto et al.
also found that use of infliximab, adalimumab, and golimu-
mab, as opposed to etanercept or certolizumab pegol, was
clearly more advantageous for achieving bDMARD-free
remission in a retrospective registry study of patients
discontinuing bDMARDs [40]. This is in line with the
current findings, which also showed that patients who were
using an anti-TNF monoclonal antibody (mostly adalimu-
mab) were significantly more often able to successfully dis-
continue their TNFi than patients who had been using a
receptor antagonist (mostly etanercept). These findings
might be explained by several differences between the TNF
receptor antagonists and antibodies. Firstly, TNF receptor
antagonists function as decoy receptors that bind to circu-
lating TNF, thereby mimicking the inhibitory effects of nat-
urally occurring soluble TNF receptors, albeit with a greatly
extended circulatory half-life. TNF antibodies also bind spe-
cifically to TNF and thus block its interaction with the p55
and p75 cell surface TNF receptors. However, TNF anti-
bodies may also lyse surface TNF expressing blood cells in
the presence of complement thereby possibly inducing
prolonged disease control [20–23]. Secondly, pharmacoki-
netic properties differ between the drugs, with a single dose
half-life of approximately 4 days for the TNF receptor an-
tagonists etanercept vs. 10–20 days for the TNF antibody
adalimumab [20]. Finally, there may be differences in drug
dosages and dosage-intervals.
This current post-hoc analysis used a relatively large data-
set collected in the POET study, a randomized controlled
trial on stopping TNFi in RA patients in daily clinical prac-
tice. The subgroup of 439 patients appeared to be an un-
biased sample of the total stop group. With an average age
of 60 years and a median disease duration of 10 years, the
sample also appeared to be representative of the population
with established RA using TNFi in The Netherlands.
However, the study also has several limitations that
should be considered. Besides the general limitations of ex-
ploratory post-hoc data analyses [41], one specific limitation
of the current analysis is that we only focused on baseline
predictors. Longitudinal (especially early) changes in vari-
ables such as the DAS28, ESR/CRP or MBDA scores could
have provided insight into the potential for monitoring of
these variables to predict relapse. Another possible limita-
tion of the POET study was the decision to leave restarting
of TNFi at the discretion of the treating rheumatologists. It
is possible that this has led to an overestimation of success-
ful disease control and bias in the population of TNFi
restarters. Finally, due to the pragmatic nature of the POET
Table 3 Multivariate associations with successful TNFi discontinuation with and without MBDA score as a predictor
With MBDA Without MBDA
Predictor OR 95% CI P OR 95% CI P
anti-TNF monoclonal antibodya 2.41 1.58–3.67 < 0.0001 2.46 1.61–3.73 < 0.0001
Disease duration < 10 yrs. 2.15 1.42–3.26 < 0.0001 2.14 1.42–3.23 < 0.0001
MBDA score≤ 44 2.00 1.10–3.64 0.023 – – –
aReference category is receptor antagonist
TNFi tumor necrosis factor-alpha inhibitors, MBDA multi-biomarker disease activity, OR Odds ratio. Hosmer and Lemeshow with MBDA χ2(5) = 1.57, P = 0.905, area
under ROC curve = 0.66 (95% CI: 0.61–0.71, P < 0.0001); Hosmer and Lemeshow without MBDA χ2(2) = 0.00, P = 1.000, area under ROC curve = 0.65 (95% CI:
0.59–0.70, P < 0.0001)
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study, a small proportion of patients were still using pred-
nisone at baseline, even though current guidelines clearly
state that glucocorticoids should have been withdrawn
before bDMARDs are tapered [9].
Conclusions
In patients with established RA in sustained remission
or with stable LDA, use of an anti-TNF monoclonal
antibody, disease duration less or equal to 10 years and
low to moderate MBDA score at the time of discontinu-
ation were significantly associated with success of stop-
ping TNFi. Although their predictive ability was only
modest, it may be useful to consider these clinical char-
acteristics when deciding to stop TNFi treatment in RA
patients in daily clinical practice. The current findings
and robustness of the specific predictors should be con-
firmed in other samples of RA patients stopping TNFi
treatment. Also, future studies could focus more on the
predictive value of early changes in disease-related vari-
ables and on other potential markers for successful TNFi
discontinuation.
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